Shanghai Ennovabio Pharmaceuticals Co., Ltd.

Danyi Wu

Lei Jiang

Yuan Xu

Ke Shang

Jianyong Shou

Yi Zhang

Zhiyong Feng

Mingwei Zheng

Jianwen Deng

Jianhua Zhang

Haixia Zhao

Bing Wang

Xiaoping Xie

Zhi Qiao

Xueli Xu

Shengyang Liu

Xian Jin

Xudong Mao

Shuyun Zhang

Yuxing Zhang

Lingling Xu

Xiaoli Lu

A class of five-membered fused with six-membered heterocyclic compounds represented by formula I and a pharmaceutical composition, preparation, and an application thereof are disclosed. These compounds have TRK kinase inhibitory activity and can treat diseases related to TRK dysfunction.

Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor

Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.

Aromatic heterocyclic compound with kinase inhibitory activity

Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.

Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

Growing community of inventors

Shanghai, China

Danyi Wu